Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Should of kept my mouth shut. 52w low....OTCN sitting with 1m on the ask.
Looking a little better today. OTCN has stayed at .004 all day....
kt
Grabbed some of this today.
Thanks,
kt
Not a bad lotto for 2 cents...I've gambled on worst lol!
Blank check company...they have until May 1st to complete a merger....I believe the warrants become worthless if they cease operations and don't complete a merger.
https://ih.advfn.com/stock-market/NASDAQ/anthemis-digital-acquisi-ADAL/stock-news/89550370/quarterly-report-10-q
The Company will have only until May 1, 2023 (the “Combination Period”) to complete the initial Business Combination. If the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $100,000 of interest to pay dissolution expenses and net of taxes payable), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
kt
About 2/3 down the site........strange to be in there with the big boys...humm
Might grab some more down here today.
Stocks On Our Radar:
AgeX (NYSE: AGE) ?? – $3.00 target
Portage Biotech (NASDAQ: PRTG) – $25 target ??
Tesla Inc. (NASDAQ: TSLA) $400 target??
Palantir Technologies Inc. (PLTR: NYSE) Big (beta) upside. $25 target ??
M2Bio Sciences (OTC: MRES) ??
https://internetbullreport.com/the-weekly-bull-report-february-12-2023-%f0%9f%97%9e/
Can Psychedelics Solve the Youth Mental Health Crisis?
Nearly two-thirds of young adults report having either depression or anxiety. In California, Connecticut, Illinois, and other states, lawmakers are considering their options for psychedelics legalization.
By Isaac LozanoTwitterFEBRUARY 3, 2023
Ketamine Clinic
At Boulder Mind Care, Dr. Wade Grindle gives ketamine to some patiences to help with their depression. (RJ Sangosti / Getty)
As a high school freshman, Aiden McDonnell began exploring dissociative drugs with the help of well-connected friends: first with DXM, a cough suppressant often found in over-the-counter medicine, and later with magic mushrooms and LSD. His initial experiences with these substances—typically labeled “psychedelic” for their visual or illusory effects—were “not fun” and spawned regrets over losing “the innocence of childhood,” said McDonnell. “That’s probably not the best when you haven’t even started figuring stuff out.”
But now McDonnell, 19, is more careful with psychedelics, which he says have helped him understand himself better. His foray into recreational substances isn’t unique and is increasingly common among his generation. According to federal survey data, 8 percent of young adults reported using psychedelic drugs in 2021, up from 3 percent a decade prior. Growing cultural acceptance along with a nascent field of research with promising implications for treating depression have positioned psychedelics as a potential aid to a youth mental health crisis. Nearly two-thirds of young adults report having either depression or anxiety. In 2019, 9 percent of high school students reported attempting suicide during the previous 12 months, and suicide remains one of the leading causes of death for teenagers.
In California, Connecticut, Illinois, and other states, lawmakers are considering their options for psychedelics legalization. And in cities like Oakland, for example, psychedelics remain illegal by state and federal law but have been effectively decriminalized by placing them as the lowest priority for the city’s police department. Full legalization of psychedelic possession, however, remains scant, as legislators hesitate to open paths for recreational use. On the federal level, at least one substance, MDMA, has passed its first Phase 3 trial, needing only a second successful trial before it may be approved for medical use by the Food and Drug Administration.
But some parents have already turned to psychedelic clinics to alleviate their children’s mental health conditions. When Lori Calabrese, a physician and researcher from Windsor, Conn., began administering ketamine, some of her patients suggested the drug for their teenagers who struggled with depression and anxiety. As Calabrese did more research and conducted her own clinical trials, she realized that adolescents, who are often excluded from research trials or clinical treatments with psychedelics, could benefit tremendously. One 2021 study by researchers at Yale, which used 17 adolescents ages 13 to 17 who had major depressive disorder, found that 76 percent experienced relief within three days of receiving ketamine infusions. Calabrese attributes these improvements to neuroplasticity—the ability of the brain to form new neural pathways and adapt to environmental changes—which occurs at all ages but might be “especially vibrant in a teenager or a young adult.”
For a depressed mind, taking ketamine is like “getting a download of all kinds of perceptions, ideas, thoughts,” said Calabrese. “It’s sort of like you’re a stalled car, and ketamine is giving you some juice and a key in the ignition.” And for many, it can be the difference between suicidal thoughts and a realization that “Oh my gosh, I’m really loved,” according to Calabrese. Her work with teens led her to publish a 2019 study, which included adolescents, that found that ketamine infusions could dramatically decrease the likelihood of ER visits and suicide attempts.
Rebecca Hendrix, a psychotherapist in New York who administers ketamine-assisted therapy, sees a strong medicinal potential in psychedelics. Her young clients are less receptive to alcohol and hard drugs, such as fentanyl, and seem “more hardwired for taking care of themselves and a healthy lifestyle.” Federal and polling data show that young people, despite increasingly consuming marijuana and psychedelics, are steering away from opiates and, at least compared to older generations, drinking less. What’s more, Hendrix notes, is that many young adults are looking for alternative methods of mental health treatment. “What’s available to them is to take an SSRI every day for maybe the next 10, 20 years or the rest of their life,” said Hendrix. “A lot of times, the medications that are out there address the symptoms, but not the core.”
Burke Ramirez knows personally that taking anti-anxiety medication “was not really a pleasant experience.” Having taken meds throughout high school, Ramirez says he’s still dealing with the side effects. Though he’s had mixed experiences with psychedelics, he believes that they have led to “a lot of self-reflection” and that they should be widely available to those who may benefit from them. “To me, it’s just expanding the doctor’s toolbox.… if one chemical advantage can be extremely effective, it’d be such a shame to not let that be utilized for people.”
CURRENT ISSUE
View our current issue
Subscribe today and Save up to $129.
But whether these potential benefits warrant immediate legislative action—especially for already vulnerable groups—is less clear. Though their long-term effects are not yet fully understood, psychedelics are generally considered nontoxic and carry little risk of a fatal overdose, unlike harder drugs like heroin or crystal meth. Kimberly Juroviesky, president of the insurance advocacy group Ketamine Taskforce, knew a patient who developed major bladder issues after four years of receiving two normal doses of ketamine every week. “Now we’re realizing it’s not just about the dose, even if it’s much smaller. When you keep hammering the bladder with ketamine, it still can cause the same side effects,” Juroviesky says. But if “used appropriately” and with sufficient time in between doses, the drug “can be very safe.”
In New York, legal possession of psychedelics—whether for medical or recreational use—might soon be a reality. Assembly member Linda Rosenthal filed a bill in December that would legalize possession of natural psychedelics, including magic mushrooms, for adults ages 21 and over. Though it excludes synthetic psychedelics like MDMA, which Rosenthal says is a tactical move to increase support for the bill, and does not legalize the sale of psychedelics, it would help existing therapeutic communities and practitioners to safely conduct psychedelic-assisted mental health treatment. “A bill like this is hard enough,” Rosenthal told The Nation. But whether Republicans help make psychedelics a bipartisan effort is something “we’ll have to see.” Most recently, Arizona Republicans joined Democrats to propose a bill to fund magic-mushroom trials for PTSD research. And if New York “passes something and has a great impact, other states consider it.”
Another New York Assembly member, Pat Burke, also filed a separate bill this winter that would establish medical facilities for psilocybin mushrooms to be grown and administered to patients. According to Avery Stempel, who has met with state legislators alongside the New York Psilocybin Action Committee, Burke’s bill likely stands a higher chance of passage thanks to its primarily medical approach. “We want the Linda Rosenthal bill,” Stempel says, “but unfortunately, New York will not open the floodgates to pure decriminalization without first working it through a medicinal mode.”
Some researchers, however, still urge caution. Professor of psychiatry and behavioral sciences at Stanford University Robert Malenka worries that governments may be rushing to conclusions prematurely without sufficient scientific consensus. If more states and cities decriminalize or fully legalize psychedelics, opening the path for broad recreational use across the country, Malenka said, “there is no doubt that their use will increase and that will increase the numbers of individuals who have bad or even dangerous experiences.”
DONATE NOW TO POWER THE NATION.
Readers like you make our independent journalism possible.
Others see a more complicated picture. Executive Director for Students for Sensible Drug Policy Jason Ortiz believes that criminalizing psychedelics is wrong from a moral and practical standpoint. He points to broad policy reports suggesting that drug penalization fails to prevent addiction and, in some cases, only further undermines public health by prioritizing carceral solutions. “We should not be making policy based on fear,” said Ortiz. “All the negative side effects of drugs can be approached from a place of compassion, and reduced.… But none of that requires prohibition or law enforcement to deny anyone the ability to try it.” Given millennials’ broad support for progressive rehabilitative policies, youth support for psychedelic decriminalization may be substantial. “I think a lot of young people wouldn’t necessarily consider themselves anti-drug,” says Aaron Genuth, a legislative coordinator with the New York Psilocybin Action Committee. “People have become a lot more aware of the degree to which the drug war hasn’t worked, and has been rooted in racism, classism, falsehoods, and violence.”
But even if states like New York legalize psychedelics, it might not be enough. Particularly for young people, accessibility may prove to be the biggest challenge; costs for full psychedelic treatment can exceed $4,800, and some psychedelic companies are pursuing patents to ensure their future profits. Passing the first wave of laws, though, is the first step for activists. “The research going back a bunch of years has been pretty exclusively positive,” said Genuth. “That’s why I say it’s a matter of when, not if.”
https://www.thenation.com/article/politics/psychedelics-legalization-ketamine-treatment-youth-depression-anxiety/
Biotechs scramble as Australia leads world in psychedelics
Julie Hare
Julie Hare
Education editor
Feb 6, 2023 – 5.00am
Biotechs backed by billionaires Andrew Forrest and Gina Rinehart are racing to get psychedelic therapies ready for market after Australia became only the second country to approve their use to treat depression and PTSD.
ASX-listed Emyria’s managing director Michael Winlo, backed by Mr Forrest, said the Therapeutic Goods Administration had made a “remarkable” turnaround after it put the brakes on rescheduling psilocybin and MDMA for use in clinical settings in December.
Michael Winlo, CEO of Emyria, says the TGA’s approval of psychedelic drugs opens the door to exciting new therapies. Trevor Collens
Use of the drugs by psychiatrists could now be as soon as July. “The fact that they actually responded to this growing body of evidence in this positive way, is remarkable,” Dr Winlo said.
Shaun Duffy, the chief executive of Reset Mind Services – a subsidiary of medicinal cannabis company Little Green Pharma, backed by Ms Rinehart – said his company was ready to go as soon as qualified psychiatrists had been approved to prescribe the drugs.
“We already have got documented protocols for treatment-resistant depression, we’ve already got ethics approval in a clinical trial which has taken nearly two years of work,” Mr Duffy said.
“There are companies like us that are well down the track. But your suburban psychiatrist is not going to be able to just open a practice to do this. It’s going to be people within that community who have already done a lot of background work in a trial environment leading up to it.”
Shaun Duffy, CEO of psychedelics company Reset Mind Sciences. Tony McDonough
Drug developers, academics and lobbyists in the close-knit community of psychedelic therapies were surprised the TGA’s decision on Friday.
As recently as December 15, the TGA deferred a decision to reschedule the two drugs from schedule 9 (prohibited drug) to schedule 8 (controlled drug) “pending a review into the therapeutic value, risks and benefits to public health outcomes for these substances”.
Under the TGA decision, psychiatrists who have been approved by a human ethics committee can prescribe psilocybin for depression and MDMA for post-traumatic stress disorder only if the conditions are long-term and have not responded to other therapies.
The drugs can also only be used as part of a longer-term psychotherapy program. The only other country in the world that has approved the use of psychedelics is Canada.
Philanthropist Peter Hunt, chairman of lobby group Mind Medicines Australia, said: “There’s no end of patients with treatment-resistant depression and PTSD that we’ve got psychiatrists already putting up their hands and saying they’ve got patients for whom this is appropriate.”
Nearly 9 per cent of Australians suffer from a chronic mental health condition and consultant LEK Consulting said the therapies could be a major disrupter to the global $25 billion market in conventional drug treatments, which are often ineffective for many patients.
Josh Ismin from Psylo which, like Emyria, has received backing from Mr Forrest’s biotech venture capital fund Tenmile, said it “was really ambitious” to imagine that psychedelics could be prescribed as early as July.
Psylo founders Sam Banister and Josh Ismin.
“There will be political pressure and people pointing fingers at the TGA. It’s still going to be case by case with psychiatrists getting approval. It will take a long time for things to scale up to any sort of degree where many desperate people will have solutions available to them. It’s going to book out well in advance. But it is a step in the right direction,” Mr Ismin said.
Mr Hunt said medical grade psilocybin had already been imported from Canada and MDMA was ready to be flown here.
Psychiatrist Eli Kotler said the decision was the right one, but he harboured concerns that enthusiasm for psychedelics could get out of hand.
“A lot needs to be done to prepare the eco-system for these medication-assisted therapies before July,” Dr Kotler said.
“I also worry about the rush of people looking for a psychiatrist that can ‘cure them’ with these medicines. In truth, healing from chronic mental health conditions will always require intensive, difficult and painful psychological therapy, which these medicines can facilitate in the right person, at the right time, with the right support. They are not a magic panacea, or a spiritual miracle-worker or a personal messiah.”
Dr Winlo said the decision opened the door to exciting new therapies.
“The potential of these drugs that operate on most of the major neurotransmitter pathways of the mind is fascinating,” he said.
“These pathways are involved in mood, satisfaction, alertness and attention. We believe it’s possible to make changes to these molecules to tune their selectivity to generate treatments that could be applied for neurodegenerative disorders like Parkinson’s disease.
“There’ll be a range of innovation that’s now possible through the rescheduling of these drugs. We’re going to see a huge flurry of innovation in Australia.”
Opposition health spokeswoman Anne Ruston said the TGA’s decision had been based on “the relevant evidence and professional advice”.
“Our health regulators have an important role to play to ensure that access to medicine and pharmaceuticals are prescribed appropriately and in line with the relevant regulations,” Ms Ruston said.
Steve Burnell, Tenmile’s executive chairman, said the TGA’s decision was based on sound and evolving evidence that psychedelics could be profoundly helpful in treating complex neurological disorders.
“This decision provides important new options and, equally importantly, will accelerate further research on this class of medicines.”
https://www.afr.com/life-and-luxury/health-and-wellness/biotechs-scramble-as-australia-leads-world-in-psychedelics-20230205-p5chzg
$MRES $ 0.0108@contrariansmind
— TheLionAndTheLamb (@CrowningProfits) February 9, 2023
I'm curious if that's the 🇨🇦 investing legend Sheldon Iwentash @sheldonstash
next to you. https://t.co/eeckSyNhYH @ThreeDCap pic.twitter.com/byZdBe1ejh
Small add of 50k at .01. Hopefully close to a bottom.
Kt
No idea but from Oct 1st to the end of Jan 2023 the OS went from 960m to over 1B. That's 40M plus added to the OS. Maybe I'm just starting to lose patience on this one. :(
kt
FYI..MM STXG has been relentless lately.
kt
Just added 100k here at .0119.
kt
Don't know but VERT must of just took a potty break....he's back.
MM VERT has been pushing it down all day....he just left...hopefully he's finished!
kt
Starter here at .011...been watching a while. Hopefully this symbol treats me better than the last one lol.
kt
GTSM(the old CANT for those of us that go back a few years) on bid...will be interesting to see if he stays there.
kt
Agree...looks like they did the same filing in 2021 and 2019.
Back to waiting.....
Saw that too so who knows??
Only site I can find online??
https://opencorporates.com/filings/1147651098
kt
Keep $SLV on watch. $AGQ options are how I’m playing it. Hope all is well and hope you had a great Thanksgiving!!
Added 5k here at .19....willing to wait for this one.
kt
Picked up a starter here....pretty good support around .12.
kt
ASCM loves to short on these low volume days!
Added some more here at .68....maybe they'll hit my .60 order. Low volume shakeout.
kt
On our way to 1m traded today!
Nothing left...Boom!
kt
lol...yup. 70k here...idiots lol
No kidding. That company is toast! I can't believe that there are still idiots holding shares lol.
We are undertaking to file the S-4 registration statement, which will be filed as soon as a pending audit of the financial statements of the acquired CareClix companies is completed.
Here we go again with the audit financial statements.....they should be ready to go since they've been preparing them for months!
Now revenues...unaudited of course. For the year ending May 2021 CareClix had 6.2m in revenue. For the 9 months ending in Feb 2022 they only had 1.9m in revenue?? So under 3m in revenue this year?? So much for all the talk of 25-30m a year in revenue....$hit show continues!
https://ih.advfn.com/stock-market/USOTC/life-on-earth-pk-LFER/stock-news/87859136/quarterly-report-10-q
kt
True....I'll probably be one of them. Hard to hold anything overnight in this market.
Don't know why anyone would want to be long over the weekend....since that's my thinking we'll probably gap up on Tuesday lol.
Nice call!!
Grabbed a couple 220 lotto puts. Hope all is well!!
kt
Yep that too lol!
This one kinda close to home??
https://news.yahoo.com/louisville-mayoral-candidate-shot-attempted-171738161.html
Pretty sad!!
Hope all is well....not playing too much lately. Although the direction is down, these bear rallies can hurt if you're holding overnight!
kt